Repros Therapeutics Inc (RPRX): 3. Cost effects P3 trials. Duh. 4....

S&P 500

US TECH 100

Dow Jones

Brent Oil

Bitcoin

Repros Therapeutics Inc (RPRX)

Reply Private New

Keep Last Read

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	89
Posts	18053
Boards Moderated	0
Alias Born	09/06/2006

Re: io_io post# 3618

Monday, 03/03/2008 8:08:23 PM

Monday, March 03, 2008 8:08:23 PM

3. Cost effects P3 trials.

Duh.

4. Clinical effect vs. stat sig

This is a point that David at BSR has been pounding the drums on. Running a 2000 patient trial to detect a microscopic improvement in some clinical condiction is just not impressive.

5. Bigger trials might be bad because safety issues could outweight benifit.

Sorry, unless I misunderstand you, you lost your mind on this one.

Keep Last Read

Replies (1) Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

1D
1M
3M
6M
1Y
5Y

Detailed Quote

Recent RPRX News

Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/06/2024 02:24:14 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2024 12:35:00 PM
Royalty Pharma Reports Third Quarter 2024 Results • GlobeNewswire Inc. • 11/06/2024 12:15:00 PM
Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo • GlobeNewswire Inc. • 11/04/2024 09:15:00 PM
Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™ • PR Newswire (US) • 11/04/2024 09:01:00 PM
Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024 • GlobeNewswire Inc. • 10/16/2024 08:15:00 PM
Royalty Pharma Declares Fourth Quarter 2024 Dividend • GlobeNewswire Inc. • 10/11/2024 12:15:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 09/27/2024 12:39:00 PM
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement • GlobeNewswire Inc. • 09/03/2024 09:14:32 PM
Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement • GlobeNewswire Inc. • 09/03/2024 09:06:29 PM
Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference • GlobeNewswire Inc. • 08/28/2024 08:15:00 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/12/2024 11:20:32 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/12/2024 11:19:02 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/12/2024 11:17:16 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 01:02:22 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 11:20:53 AM
Royalty Pharma Reports Second Quarter 2024 Results • GlobeNewswire Inc. • 08/08/2024 11:00:00 AM
Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 11:04:01 AM
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 07/29/2024 08:30:11 PM
Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital • GlobeNewswire Inc. • 07/24/2024 12:30:00 PM
Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024 • GlobeNewswire Inc. • 07/19/2024 12:15:00 PM
Royalty Pharma Declares Third Quarter 2024 Dividend • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 12:03:31 PM
Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:58:32 PM
Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 09:06:32 PM

More RPRX News

InvestorsHub NewsWire

VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM

Rainmaker Worldwide Inc. Announces Strategic Partnership Between Miranda Water Technologies and Fleming College • RAKR • Nov 4, 2024 12:03 PM

North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • NBRI • Nov 4, 2024 9:00 AM

Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM

CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM

Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM

Start posting your company's news

Only $200 per official company press release!

InvestorsHub community

Register for free to join our community of investors and share your ideas

You'll also get access to streaming quotes, interactive charts, trades, portfolio, live options flow